| Literature DB >> 32009862 |
Cherry Wl Lau1, Thomas Mok1, William Wn Ko1, Bobby Hp Ng1, Irene Hl Chan1, Teresa Ts Tsui1, S O Ling1, H Y Kwan1, Y N Poon1, C W Yim1, P Y Yau1.
Abstract
BACKGROUND ANDEntities:
Keywords: Chronic obstructive pulmonary disease; activities of daily living; physical and rehabilitation medicine; pulmonary rehabilitation programme; survival analysis
Year: 2019 PMID: 32009862 PMCID: PMC6967225 DOI: 10.1177/1569186119882772
Source DB: PubMed Journal: Hong Kong J Occup Ther ISSN: 1569-1861 Impact factor: 0.917
Figure 1.Consort diagram of the study. ADL: activities of daily living; COPD: chronic obstructive pulmonary disease; PRP: pulmonary rehabilitation programme.
Demographics of participants.
| Demographics | n (%) |
|---|---|
| Sex (Male) | 395 (91.6%) |
| PRP completion rate | 299 (69.4%) |
| LTOT use | 188 (43.8%) |
| Moser’s ADL class | 346 (81%) |
| GOLD spirometric classification (n = 396) | |
| Stage 1 | 12 (3.0%) |
| Stage 2 | 91 (23.0%) |
| Stage 3 | 185 (46.7%) |
| Stage 4 | 108 (27.3%) |
Mean | |
| FEV1 (n = 400) | 0.9 L |
| FEV1 predicted (n = 395) | 41.08% |
| FVC (n = 396) | 2.17 L |
| MFTE score (on PRP admission) (n = 424) | 17.0 |
| CRQ: Dyspnoea (n = 423) | 22.5 |
| CRQ: Fatigue (n = 423) | 18.2 |
| CRQ: Emotion (n = 423) | 35.9 |
| CRQ: Mastery (n = 424) | 19.7 |
ADL: activities of daily living; CRQ: Chronic Respiratory Disease Questionnaire; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: global initiative for chronic obstructive lung disease; LTOT: long-term oxygen therapy; PRP: pulmonary rehabilitation programme.
Figure 2.Causes of death according to ICD-10. AMI: acute myocardial infarction; CHF: chronic heart failure; COPD: chronic obstructive pulmonary disease.
Figure 3.Kaplan–Meier analysis for all recruited subjects (n = 431).
Figure 4.Kaplan–Meier analysis for all recruited subjects (n = 431), age group as strata.
Results of cox regression analysis.
| Age groups | Parameters | Significance | Exp(B) | 95.0% CI for Exp(B) | |
|---|---|---|---|---|---|
| Lower | Upper | ||||
| Age <72 | Sex | 0.140 | .607 | .313 | 1.178 |
| Moser’s ADL class |
| .486 | .258 | .915 | |
| CRQ dyspnoea score | 0.106 | .959 | .912 | 1.009 | |
| CRQ fatigue score | 0.214 | 1.048 | .973 | 1.129 | |
| CRQ emotion score | 0.263 | 1.026 | .981 | 1.073 | |
| CRQ mastery score | 0.217 | .965 | .912 | 1.021 | |
| LTOT use | 0.935 | 0.977 | .555 | 1.718 | |
| FEV1 predicted | 0.762 | .997 | .979 | 1.016 | |
| FVC | 0.458 | .860 | .578 | 1.280 | |
| PRP completion |
| .523 | .320 | .855 | |
| MFTE score ≥17 | 0.054 | 1.766 | .990 | 3.152 | |
| Age ≥72 | Sex | 0.730 | .913 | .542 | 1.536 |
| Moser’s ADL class | 0.737 | .927 | .595 | 1.443 | |
| CRQ dyspnoea score | 0.928 | 1.002 | .966 | 1.039 | |
| CRQ fatigue score | 0.276 | .971 | .922 | 1.024 | |
| CRQ emotion score | 0.424 | 1.011 | .984 | 1.039 | |
| CRQ mastery score | 0.560 | .987 | .945 | 1.031 | |
| LTOT use | 0.330 | 1.183 | .844 | 1.657 | |
| FEV1 predicted | 0.495 | .996 | .985 | 1.007 | |
| FVC | 0.139 | 1.220 | .937 | 1.589 | |
| PRP completion | 0.161 | .789 | .567 | 1.099 | |
| MFTE score ≥17 |
| .557 | .403 | .769 | |
ADL: activities of daily living; CRQ: Chronic Respiratory Disease Questionnaire; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: global initiative for chronic obstructive lung disease; LTOT: long-term oxygen therapy; MFTE: Modified Functional Tasks Evaluation; PRP: pulmonary rehabilitation programme.
*p ≥0.05.
Figure 5.Kaplan–Meier analysis for age <72 subjects (n = 168), ADL class as strata. ADL: activities of daily living.
Figure 6.Kaplan–Meier analysis for age <72 subjects (n = 169), PRP completion as strata.
Figure 7.Kaplan–Meier analysis for age ≥ 72 subjects, MFTE score as strata. MFTE: Modified Functional Tasks Evaluation.
Comparison of survival outcomes among patients after PRP in different studies.
| Current study |
| Voogd et al. 2009 |
|
|
| |
|---|---|---|---|---|---|---|
| Country/region | Hong Kong | Norway | Netherland | Canada | Uruguay | Portugal |
| Age | 72 | 69 | 62 | 69 | 64 | 69 |
| Duration | 4 Months | 8 weeks | 6 months | 3 weeks | 3 months | 12–16 weeks |
| Survival years | Overall – 4.1 | 6.7 | 5.3 | 3.0 | N/A | N/A |
| Survivalpredictors | (Age<72) | N/A | Gender, age, peak power output, depressive symptoms | 6MWT | FEV1, 6MWT, cycle ergometer workloads | Lung cancer, respiratory failure, noninvasive ventilation, previous hospitalisation, 6MWT |
ADL: activities of daily living; FEV1: forced expiratory volume in 1 s; MFTE: Modified Functional Tasks Evaluation; PRP: pulmonary rehabilitation programme; 6MWT: six-minute walk test.